Abstract
The discovery and development of an efficient, practical asymmetric synthesis of the HIV Protease inhibitor CRIXIVAN® is described. Particular emphasis is placed on the selective installation of each of the five stereogenic centers as well as design strategies associated with the preparation of a complex pharmaceutical agent needed in multiton quantities.
Original language | English (US) |
---|---|
Pages (from-to) | 306-308 |
Number of pages | 3 |
Journal | Chimia |
Volume | 51 |
Issue number | 6 |
State | Published - 1997 |
Externally published | Yes |
All Science Journal Classification (ASJC) codes
- General Chemistry